Hormonal treatment in advanced non-small cell lung cancer: Fact or fiction?

European Respiratory Journal

Volumn 9, Issue 8, 1996, Pages 1707-1712

  Vansteenkiste, J F ^a   Simons, J P ^b   Wouters, E F ^b   Demedts, M G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer anorexia and cachexia syndrome; Lung neoplasms; Palliative treatment; Progestagens

Indexed keywords

CORTICOSTEROID; CYPROHEPTADINE; GESTAGEN; HORMONE; HYDRAZINE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METOCLOPRAMIDE; NANDROLONE DECANOATE; TETRAHYDROCANNABINOL;

ANOREXIA; CACHEXIA; CANCER HORMONE THERAPY; CORTICOSTEROID THERAPY; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0029764890     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09081707     Document Type: Short Survey

References (48)

1. Vansteenkiste J, Weyler J, Thibaut A, et al. A hospital-based lung cancer registry in Flanders/Belgium: recent data and survival analysis on 2,709 patients. Lung Cancer 1994; 11 (Suppl.): 53 (Abstract).
2. Rapp E, Pater J, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641.
3. Souquet P, Chauvin F, Boissel S, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
4. Jaakkimainen L, Goodwin PJ, Pater JL, et al. Counting the costs of chemotherapy in National Cancer Institute of Canada: randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301-1309.
5. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer, Br J Cancer 1995; 71: 366-370.
6. Theologides A. Cancer cachexia. Cancer 1979; 43: 2004-2020.
7. Kern KA, Norton JA. Cancer cachexia. J Parent Ent Nutr 1988; 12: 286-298.
8. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491-497.
9. Nixon DW, Heymsfield SB, Cohen AE, et al. Protein-calorie undemutrition in hospitalized cancer patients. Am J Med 1980; 68: 683-690.
10. Feld R, Arriagada R, Ball D, et al. Prognostic factors in non-small cell lung cancer: a consensus report. Lung Cancer 1991; 7: 3-5.
11. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
12. Nelson K, Walsch D, Shechan F. The cancer anorexia cachexia syndrome. J Clin Oncol 1994; 12: 213-225.
13. Fredrix EW, Wouters EF, Soeters PB, et al. Resting energy expenditure in patients with non-small cell lung cancer. Cancer 1991; 68: 1616-1621.
14. Staal AJ, Schols AM, Ten Velde G, Buurman WA, Wouters EF. Analysis of the energy balance in lung cancer patients. Cancer Res 1994; 54: 6430-6433.
15. Staal AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995; 13: 2600-2605.
16. Heber D, Chlebowski RT, Ishibashi DE, Richardson B, Block JB. Abnormalities in glucose and protein metabolism in noncachectic lung cancer patients. Cancer Res 1982; 42: 4815-4819.
17. Costa G, Lane WW, Vincent RG, Siebold JA, Aragon M, Bewley PT. Weight loss and cachexia in lung cancer. Nutr Cancer 1981; 2: 98-103.
18. Brennan MF. Supportive care of the cancer patient. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principals and Practice of Oncology. Philadelphia, Lippincott. 1985; pp. 1907-1920.
19. Muller JM, Brenner U, Dienst C, Pichlmaier H. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1982; i: 68-71.
20. Clamon G, Feld R, Evans WE, et al. Effect of hyper-alimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treat Rep 1985; 69: 167-177.
21. Nixon DW. The value of parenteral nutritional support. Cancer 1986; 58: 1902-1903.
22. Klein S, Simes J, Blackburn G. Total parenteral nutrition and cancer clinical trials. Cancer 1986; 58: 1378-1386.
23. Koretz RL. Parenteral nutrition: is it oncologically logical? J Clin Oncol 1984; 2: 534-538.
24. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia. Cancer 1990; 65: 2657-2662.
25. Kosty MP, Fleishman SB, Hemdon JE, et al. Cisplatin, vinblastine and hydrazine sulfate in advanced non-small cell lung cancer: a randomized, placebo-controlled, double-blind, phase III study of the cancer and leukemia group B. J Clin Oncol 1994; 12: 1113-1120.
26. Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate in cancer patients with weight loss: a placebo-controlled clinical experience. Cancer 1987; 59: 406-410.
27. Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate influence on nutritional status and survival in non-small cell lung cancer. J Clin Oncol 1990; 8: 9-15.
28. Nelson KA, Walsh TD, Sheehan FG, O'Donovan PB, Falk GW. Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome. J Pall Care 1993; 9: 27-31.
29. Shivshanker K, Bennet RW, Haynie TP. Tumor-associated gastroparesis: correction with metoclopramide. Am J Surg 1983; 145: 221-225.
30. Nelson K, Walsh D, Deeter RP, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Pall Care 1994; 10: 14-18.
31. Moertel CG, Schutt AJ, Reitemeier RJ. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607-1609.
32. Willox J, Corr J, Shaw J, Richardson M, Calman KC, Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J 1984; 288: 27.
33. Bruera E, Roca E, Cedaro L, et al. Action of oral methyl-prednisolone in terminal cancer patients: a prospective, randomized, double-blind study. Cancer Treat Rep 1985; 69: 751-754.
34. Chlebowski R, Herrold J, Ali I, Oktay E, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986; 58: 183-186.
35. Nelson KA, Walsh TD. Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome. J Pall Care 1993; 9: 14-18.
36. Schell HW. The risk of adrenal corticosteroid therapy in far advanced cancer. Am J Med Sci 1966; 252: 641-649.
37. Wilson JD, Griffin JE. The use and misuse of androgens. Metab Clin Exp 1980; 29: 1278-1294.
38. Feliu J, Gonzalez-Baron M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 1992; 15: 436-440.
39. Loprinzi C, Ellison N, Schaid D, Krook J, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Natl Cancer Inst 1990; 82: 1127-1132.
40. Tchekmedyian NS, Hickman M, Siau J, et al Megestrol acetate in cancer anorexia and weight loss. Cancer 1992; 69: 1268-1274.
41. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ. Megestrol acetate in cancer cachexia. Semin Oncol 1991; 18 (Suppl.): 32-34.
42. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279-1282.
43. Simons JP, Aaronson NT, Vansteenkiste JF, et al. The effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non-hormone-sensitive cancer: a placebo-controlled, multicenter study. J Clin Oncol 1996; 14: 1077-1084.
44. Niiranen A, Kajanti M, Tammilehto L, Mattson K. The clinical effect of medroxyprogesterone (MPA) in elderly patients with lung cancer. Am J Clin Oncol 1990; 13: 113-116.
45. Downer S, Joel S, Allbright A, et al. A double-blind, placebo-controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993; 67: 1102-1105.
46. Pannuti F, Martoni A, Dimarco AR, el al. Prospective randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer. Eur J Cancer 1979; 15: 593-601.
47. Aaronson N, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
48. Simons JP, Schols AM, Hoefnagels JM, et al. The effects of medroxyprogesterone acetate (MPA) on energy intake and body composition in patients with advanced cancer. Proc ASCO 1995; 14: 430 (Abstract).